Shigeru Tsuyuki1, Ayane Yamaguchi2, Yukiko Kawata3, Kosuke Kawaguchi4. 1. Department of Breast Surgery, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka City, Osaka, 543-8555, Japan. Electronic address: tyksgr@osaka-med.jrc.or.jp. 2. Department of Breast Surgery, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka City, Osaka, 543-8555, Japan. 3. Department of Breast Surgery, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka City, Osaka, 543-8555, Japan; Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. 4. Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Abstract
BACKGROUNDS: It is not clear how lymphatic pathways to the sentinel lymph node (SLN) change during neoadjuvant chemotherapy (NAC) for breast cancer. METHODS: Using the indocyanine green (ICG)-fluorescence method, we compared lymphatic pathways to the SLN (sentinel lymphatic pathways) and SLN location before and after NAC in 36 patients (38 breasts). RESULTS: Despite that 42.8% of the sentinel lymphatic pathways were changed by NAC, the locations of the SLNs were not affected by NAC. CONCLUSION: These results suggest that the true SLN can be detected even after NAC, and that SLNB can be performed after NAC for clinically node-negative patients.
BACKGROUNDS: It is not clear how lymphatic pathways to the sentinel lymph node (SLN) change during neoadjuvant chemotherapy (NAC) for breast cancer. METHODS: Using the indocyanine green (ICG)-fluorescence method, we compared lymphatic pathways to the SLN (sentinel lymphatic pathways) and SLN location before and after NAC in 36 patients (38 breasts). RESULTS: Despite that 42.8% of the sentinel lymphatic pathways were changed by NAC, the locations of the SLNs were not affected by NAC. CONCLUSION: These results suggest that the true SLN can be detected even after NAC, and that SLNB can be performed after NAC for clinically node-negative patients.
Authors: Thomas Papathemelis; Evi Jablonski; Anton Scharl; Tanja Hauzenberger; Michael Gerken; Monika Klinkhammer-Schalke; Matthias Hipp; Sophia Scharl Journal: Biomed Res Int Date: 2018-03-26 Impact factor: 3.411
Authors: C S Pinto; B Peleteiro; C A Pinto; F Osório; S Costa; A Magalhães; H Mora; J Amaral; D Gonçalves; J L Fougo Journal: Breast Cancer Date: 2022-03-19 Impact factor: 3.307